Grant of Share Options

Transense Technologies plc (AIM: TRT), the provider of specialist sensor technology and measurement systems, announces that on 16 July 2024, the Company's remuneration committee (the "Remuneration Committee") approved the grant of 125,000 share options (the "Options") to acquire ordinary shares of 10 pence each in the Company ("Ordinary Shares") to Ryan Maughan, the Company's Managing Director.

In accordance with the Company's share option scheme, the Options have an exercise price of 10 pence per Ordinary Share, being the nominal value of an Ordinary Share, and can be exercised after three years until the tenth anniversary of the grant (or earlier on a change of control) subject to the adjusted profit before taxation of the Company (excluding the contribution from the iTrack royalty) being above break even for the calendar year 2026.

Ryan Maughan is now interested in a total of 350,000 unexercised share options over Ordinary Shares in the Company.

This grant of Options brings the total number of unexercised options over Ordinary Shares as at 16 July 2024 to 1,767,500, representing 10.75% of the Company's issued share capital. The Board has previously indicated a guideline that options will be granted within an overall limit of 10% of the Company's issued share capital in any ten year period. Following consultation with major shareholders, the Board now considers it appropriate to increase the overall headroom to 15% in ten years.

The Company's remuneration policy utilises share options as an element of remuneration for all employees, and a significant element of remuneration for the executive directors and other members of the senior management team. The Remuneration Committee consider that an increase in headroom is appropriate because this policy promotes:

• creation of long term shareholder value through effective alignment of management objectives;
• enhanced recruitment, retention and reward of executive talent;
• focus on performance and business improvement across the organisation;
• meaningful widespread equity participation for all; and
• cost effective and tax efficient remuneration.

Full details will be set out in the remuneration report in the Company's annual report for the year ending 30 June 2024, which will be subject of an indicative vote of shareholders at the annual general meeting which is expected to take place in November 2024.